Thinking small, doing big: Current success and future trends in drug delivery systems for improving cancer therapy with special focus on liver cancer

Limeres, María J.; Morettón, Marcela A.; Bernabeu, Ezequiel; Cuestas, María Luján

doi:10.1016/j.msec.2018.11.001

Cited by 31 publications

(19 citation statements)

References 127 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, the poor oxygen perfusion in most kinds of tumor cells causes the elevated levels of lactic acid, resulting in weakly acidic extracellular and intracellular tumor microenvironments (Wojtkowiak et al, 2011). Lots of researchers have reported that the weakly acidic microenvironment could be used as the specific cue for anticancer drug delivery and controlled release (Huang et al, 2017;Niu et al, 2018;Farjadian et al, 2019;Limeres et al, 2019). For instance, Zhang et al reported a pH-sensitive PM which was self-assembled from poly(ethylene glycol) methyl ether-b-peptide-g-cholesterol (mPEG-b-P-g-Chol) for DOX delivery and controlled release.…”

Section: Introductionmentioning

confidence: 99%

Layer-by-layer pH-sensitive nanoparticles for drug delivery and controlled release with improved therapeutic efficacy in vivo

et al. 2020

View full text Add to dashboard Cite

In this work, a pH-sensitive liposome-polymer nanoparticle (NP) composed of lipid, hyaluronic acid (HA) and poly(b-amino ester) (PBAE) was prepared using layer-by-layer (LbL) method for doxorubicin (DOX) targeted delivery and controlled release to enhance the cancer treatment efficacy. The NP with pH-sensitivity and targeting effect was successfully prepared by validation of charge reversal and increase of hydrodynamic diameter after each deposition of functional layer. We further showed the DOX-loaded NP had higher drug loading capacity, suitable particle size, spherical morphology, good uniformity, and high serum stability for drug delivery. We confirmed that the drug release profile was triggered by low pH with sustained release manner in vitro. Confocal microscopy research demonstrated that the NP was able to effectively target and deliver DOX into human non-small cell lung carcinoma (A549) cells in comparison to free DOX. Moreover, the blank NP showed negligible cytotoxicity, and the DOX-loaded NP could efficiently induce the apoptosis of A549 cells as well as free DOX. Notably, in vivo experiment results showed that the DOX-loaded NPs effectively inhibited the growth of tumor, enhanced the survival of tumor-bearing mice and improved the therapeutic efficacy with reduced side-effect comparing with free drug. Therefore, the NP could be a potential intelligent anticancer drug delivery carrier for cancer chemotherapy, and the LbL method might be a useful strategy to prepare multi-functional platform for drug delivery.

show abstract

Section: Introductionmentioning

confidence: 99%

Layer-by-layer pH-sensitive nanoparticles for drug delivery and controlled release with improved therapeutic efficacy in vivo

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Extensive studies have been carried out during the last few decades to enhance the efficacy of chemotherapy by suppressing or evading the mechanisms of MDR. These approaches include the use of MDR modulators or chemosensitizers (79,80), improved drug delivery (81,82), RNAi therapy (83), and natural products (84).…”

Section: Strategies To Overcome Mdrmentioning

confidence: 99%

“…Nanotechnology has the power to deliver anticancer drugs and radically change chemoresistance of cancer cells by overcoming MDR (82). There are several drug delivery systems including liposomes, dendrimers, polymeric micelles, nanoparticles, polymer-drug/protein-conjugates, and carbon nanotubes.…”

Section: Enhanced Drug Deliverymentioning

confidence: 99%

“…For instance, pluronic P85 can sensitize MDR tumors to many chemotherapeutic agents through various mechanisms: (i) membrane fluidization, (ii) ATP depletion, (iii) direct interaction with the ABC efflux transporter, (iv) reduction of the GSH/GST detoxification system, (v) drug release from acidic vesicles, and (vi) incorporation into the mitochondrial membrane, thereby inhibiting cellular respiration (94). Moreover, all these nanomaterial-based drug delivery systems can be conjugated with various kinds of ligands (e.g., proteins, antibodies, and small molecules) producing the so-called actively-targeted material that favors drug targeting to specific cell surfaces and thus to specific cell populations, leading to a selective and reduced toxicity (82).…”

Section: Enhanced Drug Deliverymentioning

confidence: 99%

See 1 more Smart Citation

Multidrug Resistance in Hepatocellular Carcinoma

Duan

Huang

Bai

et al. 2019

Hepatocellular Carcinoma

View full text Add to dashboard Cite

Although there has been tremendous progress in the treatment of hepatocellular carcinoma over the past decades, multidrug resistance to chemotherapy and targeted therapy remains a major hindrance in its successful management. Multidrug resistance, whether intrinsic or extrinsic, is a multifactorial process that includes enhanced drug efflux, decreased drug uptake, intracellular sequestration, metabolic alterations, aberrant apoptotic and autophagic signaling, changes in tumor microenvironment, and acquisition of stem cell-like properties by the cancer cells. Although many experimental strategies have been developed to overcome drug resistance, translation of the knowledge to the clinic has not been crowned with success. This chapter provides an overview of the role of multidrug resistance in hepatocellular carcinoma and the potential approaches to overcome this obstacle.

show abstract

“…Nano-to-micro range biomaterials are generally used for treatment, whereas, macroscale materials, in the form of tissue engineering scaffolds, are used for study this tumor. There are many review articles on nanotechnology/nanomedicine for liver cancer therapy, such as nanoparticles (NPs) and liposomes [1][2][3][4][5][6][7][8], liver cancer diagnosis and therapy [9], and biomaterials used for targeted systems [10]. However, there are no comprehensive reviews of biomaterial-based therapy that includes an overview of materials in the nano-to-macro domain, which also includes microparticles and scaffolds, with a discussion of both systemic and local delivery applications.…”

mentioning

confidence: 99%

Liver Cancer: Current and Future Trends Using Biomaterials

Chew

Moscato

George

et al. 2019

Cancers

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the fifth most common type of cancer diagnosed and the second leading cause of death worldwide. Despite advancement in current treatments for HCC, the prognosis for this cancer is still unfavorable. This comprehensive review article focuses on all the current technology that applies biomaterials to treat and study liver cancer, thus showing the versatility of biomaterials to be used as smart tools in this complex pathologic scenario. Specifically, after introducing the liver anatomy and pathology by focusing on the available treatments for HCC, this review summarizes the current biomaterial-based approaches for systemic delivery and implantable tools for locally administrating bioactive factors and provides a comprehensive discussion of the specific therapies and targeting agents to efficiently deliver those factors. This review also highlights the novel application of biomaterials to study HCC, which includes hydrogels and scaffolds to tissue engineer 3D in vitro models representative of the tumor environment. Such models will serve to better understand the tumor biology and investigate new therapies for HCC. Special focus is given to innovative approaches, e.g., combined delivery therapies, and to alternative approaches—e.g., cell capture—as promising future trends in the application of biomaterials to treat HCC.

show abstract

Thinking small, doing big: Current success and future trends in drug delivery systems for improving cancer therapy with special focus on liver cancer

Cited by 31 publications

References 127 publications

Layer-by-layer pH-sensitive nanoparticles for drug delivery and controlled release with improved therapeutic efficacy in vivo

Layer-by-layer pH-sensitive nanoparticles for drug delivery and controlled release with improved therapeutic efficacy in vivo

Multidrug Resistance in Hepatocellular Carcinoma

Liver Cancer: Current and Future Trends Using Biomaterials

Contact Info

Product

Resources

About